Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 10 1 2016 04 08 1 6 EN Mohammad Vaezi Hematologist-Oncologist, Hematology- Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Cyrous Gharib Hematologist-Oncologist, Gilan University of Medical Sciences, Gilan, Iran Maryam Souri 3Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Ardeshir Ghavamzadeh Professor of Medicine, Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2015 10 23 2015 10 23 Background: Hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for acute leukemia. As HSCT improves the long-term survival, it is necessary to assess the late-onset complications affecting the quality of life following HSCT. Subjects and Methods: The study included 122 patients (65 male, 57 female) with leukemia (72 AML and 50 ALL) who received transplants from fully- matched siblings, unrelated donors and unrelated cord blood donors between February 2013 and August 2014 in Shariati Hospital. All study participants were over 18 years of age and had the minimum and maximum survival of 2 and 5 years, respectively. Patients who received HLA-haploidentical SCT were excluded from the study. All allogeneic recipients received busulfan and cyclophosphamide as conditioning regimen. Nobody received TBI-based conditioning regimen in this study. Patients were evaluated for cardiovascular, vision, psychological, endocrine, fertility problems and secondary malignancies one year after transplantation. Results: Data were analyzed using SPSS 15.0. Mitral and tricuspid regurgitation (TR/MR) were the most common cardiac complications (n=12, 10.5%).Thirty-nine percent of patients had psychological problems, especially depression (34%). Cataract was observed in 13% of patients and 34% complained of dry eye. Symptomatic pulmonary changes were found in 13 patients (10.6%). None of the HSCT survivors had experienced fertility before study entry. According to LH and FSH levels, 15% and 9% of females had ovarian failure, respectively. Testosterone level was less than normal in 49(84%) men and, according to their FSH and LH level, 20 (41%) had secondary hypogonadism and 29 (59%) had primary gonadal dysfunction. Conclusion: The results showed that patients who received Bu/Cy conditioning regimen experienced fewer late side effects such as cataract formation and hypothyroidism, compared to previous studies using TBI-based conditioning regimen. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/481 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/481/468

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 10 1 2016 04 08 7 12 EN Md. Fazlul Karim Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka-1000, Bangladesh Md Ismail Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka-1000, Bangladesh AKM Hasan Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka-1000, Bangladesh Hossain Shekhar Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka-1000, Bangladesh 2015 10 14 2015 10 14 Background: Thalassemia is one of the most common hereditary disorders and Beta-thalassemia major is its severe form. The present study is concerned with the analysis of liver function, thyroid function and estimation of critical serum ions as well as hematological characteristics in beta-thalassemia patients and controls. Subjects and Methods: The study included 54 patients with beta-thalassemia major and 54 healthy individuals matched by sex and age. The activity of Alanine transaminase (ALT), Alkaline phosphatase(ALP) and Aspartate transaminase (AST) were assessed in order to evaluate the liver function. Serum content of iron (Fe), calcium (Ca), magnesium (Mg), sodium (Na) and potassium (K) were also estimated. Tri iodothyronine (T3), Thyroxin (T4) and Thyroid-stimulating hormone (TSH) levels were assessed in order to evaluate the thyroid function. Hemoglobin (Hb), ferritin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration(MCHC), total iron binding capacity (TIBC) and creatinine level were also measured. Results: Significantly higher ALT (P< 0.001), AST (P< 0.05), ALP (P< 0.001) activities and lower creatinine (P< 0.001) level in beta-thalassemia patients were found in comparison to healthy individuals. Lower serum level of calcium (P<0.05), magnesium (P<0.05) and higher level of iron (P>0.05), sodium (P>0.05), potassium (P>0.05) have been found in patients in comparison to healthy individuals. Hematological parameters like Hb (P< 0.001), ferritin (P<0.05), HCT (P< 0.001), MCV (P< 0.05) and MCH (P< 0.05) have been significantly reduced in patients except MCHC (P>0.05). No significant difference was observed in thyroid function between patients and control group. Conclusions: Our study demonstrates that beta-thalassemia patients and controls have difference in liver function, thyroid function, serum contents of ions and hematological characteristics. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/375 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/375/469

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 10 1 2016 04 08 13 20 EN Shano Naseem Assistant Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh Maninderbir Kaur Senior Resident, Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh Man Sachdeva Assistant Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh Jasmina Ahluwalia Associate Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh Reena Das Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh Neelam Varma Professor and Head, Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh Subhash Varma Professor and Head, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 2015 10 15 2015 10 17 Background: Mature T/ NK-cell neoplasms are a rare group of disorders and their presentation as leukemia is even rarer. Most of the previous studies have focused on mature B-cell lineage leukemias and there is a paucity of data on mature T/NK-cell lineage leukemias. We, therefore, planned this study to analyze their spectrum, frequency, morphology and immunophenotypic features. Methods: All cases of lymphomas presenting as leukemia over a period of two and a half years were evaluated. Detailed analysis of cases with T/NK-cell lineage was done for their clinical, hematological and immunophenotypic features. Results: A total of 262 cases of mature lymphoid neoplasms presented as leukemia during the study period. Of whom, only 8 (3.1%) cases were of T /NK-cell lineage and the remaining (96.9%) were of B-cell lineage. Of 8 cases, 4 (50%) had T-prolymphocytic leukemia, 2 (25%) had chronic lymphoproliferative disorder- natural killer cell and 1 (12.5%) case of each T-large granular lymphocytic leukemia and hepatosplenic γ/δ T-NHL. Conclusion: T/NK-cell leukemias are rare. Along with clinical and morphological features, pattern of immunophenotypic markers is vital for their diagnosis and subcategorization. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/470 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/470/470

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 10 1 2016 04 08 21 29 EN Farshad Homayouni Moghadam Neurobiomedical Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Tahereh Tayebi Neurobiomedical Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Kazem Barzegar Head of the English Language Department, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 2015 10 13 2015 10 13 Background: Mesenchymal stem cells (MSCs) are multipotential cells and their therapeutic potency is under intense investigation. Studying the effect of different induction factors on MSCs could increase our knowledge about the differentiation potency of these cells. One of the most important sources of these factors in mammalian body is platelet. Platelet lysate (PL) contains many growth factors and therefore it can be used as a differentiation inducer. In the present study, the effect of PL on differentiation of rat bone marrow MSCs into cardiomyocytes was studied. Materials Methods: To study the differentiation-inducing effect of PL, MSCs were treated with 2.5, 5 and 10% PL. Early results of this study showed that PL in high concentrations (10%) induces adipogenic differentiation of MSCs. Therefore, to evaluate differentiation to cardiomyocytes, MSCs were cultured in media containing lower levels of PL (2.5% and 5%) and then cardiomyogenic differentiation was induced by treatment with 5-azacytidine. Differentiation of MSCs was evaluated using direct observation of beating cells, immunostaining and real-time PCR techniques. Results: The results of qPCR showed that treatment with PL alone increased the expression of cardiac alpha actinin (CAA) being predictable by earlier observation of beating cells in PL-treated groups. The results of staining assays against cardiac alpha actinin also showed that there were stained cells in PL-treated groups. Conclusion: The results of the present study showed that PL is a powerful induction factor for differentiation of MSCs into different cell lines such as cardiomyocytes and adipocytes. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/362 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/362/471

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 10 1 2016 04 08 30 36 EN Ghasem Janbabai Associate professor, Medical Oncologist-Hematologist, Gastrointestinal Cancer Research Center, Imam Khomeini Hospital , Mazandaran University of Medical Sciences, Sari, Iran Ramin Shekarriz Assistant professor, Medical Oncologist-Hematologist, Gastrointestinal Cancer Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran Homa Hassanzadeh Internist, Department of Internal Medicine, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran Mohsen Aarabi Assistant Professor, Epidemiologist, Mazandaran University of Medical sciences, Health Sciences Research Center, Sari, Iran Seyyedeh Samaneh Borhani General Physician, Gastrointestinal Cancer Research Center, Mazandaran University of Medical sciences, Sari, Iran 2015 11 15 2015 11 16 Background: In recent years, epidemiologic and laboratory studies have implied that vitamin D deficiency has a role in the pathogenesis of breast cancer. It has shown that vitamin D can prevent tumor progression induced by carcinogens and inhibit the carcinogenic effects of high fat diet on breast tissue and growth of tumor cells. This study aimed to evaluate serum 25-hydroxyvitamin D level and its role in relation to tumor characteristics and different stages of disease in women with breast cancer. Subject and Methods: This is a cross-sectional study on 200 patients with breast cancer at different stages of the disease. Information on age, menstrual status, BMI, and tumor characteristics were recorded. Serum 25-hydroxy vitamin D concentrations were measured by refigures dioimmunoassay (RIA). Mean and standard deviation were used to describe the data. Meanwhile, T-test and sum of squares test were used to analyze the data. P<0.05 was considered significant. Results: Among 200 patients, 47 (23.5%) had severe vitamin D deficiency, 75 (37.5 %) had mild vitamin D deficiency and 78 (39.0 %) had sufficient vitamin D levels of serum. There was a significant correlation between low vitamin D levels and advanced stage of breast cancer, particularly in postmenopausal patients. Conclusion: It seems that lower levels of vitamin D accompany worse clinicopathologic features. Thus, treatment of vitamin D deficiency in postmenopausal patients might be of great benefits. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/508 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/508/472

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 10 1 2016 04 08 37 41 EN Mohammad Ali Jalali Far Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Ali Dehghani Fard Sarem Cell Research Center-SCRC, Sarem Women’s Hospital, Tehran, Iran Saiedeh Hajizamani DiagnosticLaboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran Majid Mossahebi-Mohammadi Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran Hamid Yaghooti Department of Medical Laboratory Sciences, School of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Najmaldin Saki Health research institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 2015 10 13 2015 10 14 Background: Efficient induction of fetal hemoglobin (HbF) is considered as an effective therapeutic approach in beta thalassemia. HbF inducer agents can induce the expression of γ-globin gene and produce high levels of HbF via different epigenetic and molecular mechanisms. Thalidomide and sodium butyrate are known as HbF inducer drugs. Material and methods: CD133+ stem cells were isolated from umbilical cord blood of a newborn with minor β-thalassemia in order to evaluate the effects of these two drugs on the in vitro expression of GATA-1 and EKLF genes as erythroid transcription factors. CD133+ stem cells were expanded and differentiated into erythroid lineage, and then treated with thalidomide and sodium butyrate and finally analyzed by quantitative real-time PCR. Statistical analysis was performed using student’s t-test by SPSS software. Results: Thalidomide and sodium butyrate increased GATA-1 and EKLF gene expression, compared to the non-trty (MSI), the CpG island methylator phenotype (CIMP), and we then will discuss different screening tests and especially the latest non-invasive fecal screening test kits for the detection of CRC. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/610 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/610/566

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 11 3 2016 10 17 199 208 EN Mohammad Vaezi Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Amir Kasaeian Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran,, Iran Maryam Souri Medical Doctor Faeze Soufian Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Amir Skokri Boosjin Medical Doctor Seyed Amin Setarehdan Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Kamran Alimoghaddam Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Ardeshir Ghavamzadeh Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2016 05 27 2016 07 18 Background: This study evaluated CMV serostatus in donors and recipients of hematopoietic stem cell transplantation (HSCT) and its effects on CMV reactivation of patients and all aspects of CMV on HSCT outcomes. Subjects and Methods: Seven hundred and five adult acute leukemia patients (AML=408 and AML=297) who had undergone HSCT were included in this retrospective study. We categorized donor-recipient pairs in three risk groups: positive donors (D+) were studied as high-risk group, including either R+ or R-(n=485), R-D- as low-risk group (n=32) and R+D- as intermediate group (n=15). Results: There was no statistically difference in CMV reactivation among these risk groups (P=0.14).CMV infection rate was lower in R+D+ than R+D-(p=0.050). Multivariate analysis showed that patients developing CMV infection had lower overall survival (p=0.04, HR: 1.43, CI=1.00- 2.05) and higher non- relapse mortality (P=0.01, HR: 1.62, CI=1.11-2.38). Relapse rate did not change in CMV reactivated patients (P=0.94). Conclusion:The results of the study indicated that asCMV reactivation occurred more in R+D- patients compared to R+D+ ones, and was associated with inferior OS and higher NRM it could be suggested that in contrast to general belief, if the recipient is  seropositive ,seropositive donor is preferred to a seronegative one. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/617 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/617/559

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 11 3 2017 07 01 209 216 EN Fatere Seyedalipour Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Ava Mansouri Research Center for Rational Use of Drugs, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Mohammad Vaezi Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Kheirollah Gholami Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. AND Research Center for Rational Use of Drugs, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Molouk Hadjibabaie Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. AND Research Center for Rational Use of Drugs, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Ardeshir Ghavamzadeh Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 2016 11 23 2017 02 23 Background: Although several studies have supported a preventive and therapeutic role of vitamin D (Vit D) for different types of cancers, we face insufficient documentation in acute myeloid leukemia (AML). So, we examined whether the serum calcidiol (25(OH)D) levels at the time of induction therapy have any impact on response and relapse in AML patients. Subjects and Methods: Blood samples were collected from 65 patients on days 0 and 28th of treatment to evaluate serum concentration of 25(OH)D and its effects on complete remission (CR) achievement, relapse rate and hospitalization length. Results: Of the 65 patients who were included in the study, 38 were male (58.5%) and 27 were female (41.5%). Median age at the time of treatment was 37 years (range 15-68). 6% of the participants were older than 60 years. In regard to 25(OH)D levels, 81.5% of AML patients were deficient (levels <20 ng/ml). There was a significant difference in CR between patients with sufficient and deficient level of 25(OH)D. Deficient patients had longer length of hospitalization than those with sufficient levels. Also Vitamin D deficient patients had higher serum